Trials / Unknown
UnknownNCT03486561
Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine)
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 2,000 (estimated)
- Sponsor
- OBS Pakistan · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The rationale of MIDA trial is to determine efficacy and tolerability of ranolazine molecule among Pakistan population and obtain firsthand knowledge about the molecule ranolazine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranolazine | Ranolazine inhibits sodium and potassium ion channel currents. Inhibition of the late phase of the inward sodium current during cardiac repolarization has been well studied4. In disease states, enhanced sodium-calcium exchange due to augmented late phase of the inward sodium current activity leads to increased cytosolic calcium concentration. Intracellular calcium overload is believed to be critical to the mechanism of decreased left ventricular relaxation caused by ischemia and reperfusion. Elevated left ventricular diastolic wall tension compromises myocardial blood flow even further. |
Timeline
- Start date
- 2018-04-01
- Primary completion
- 2018-09-30
- Completion
- 2018-10-31
- First posted
- 2018-04-03
- Last updated
- 2018-04-03
Source: ClinicalTrials.gov record NCT03486561. Inclusion in this directory is not an endorsement.